A certain other Australian stem-cell company has today rallied hard on receiving a review date with the FDA of its very good trial results in treating acute graft versus host disease (aGVHD), a potentially life-threatening complication of an allogeneic bone marrow transplant which sees something like 50% of recipients with issues. Its very likely to get approval in a scheduled late September date for ruling by the FDA.
An Australian company going commercial with a stem-cell product in America in 4Q 2020, bodes very well for OCC from regulatory, patient, media and other contexts. I've often cited on here, the FDA's acceptance of stem-cells as valuable medical treatments, where they are backed by years of proven treatment and study - who do we know who fulfills that criteria I wonder....?
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
0.040(3.28%) |
Mkt cap ! $308.4M | |||
| Open | High | Low | Value | Volume |
| $1.22 | $1.27 | $1.21 | $737.5K | 596.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6407 | $1.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 3550 | 1 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| OCC (ASX) Chart |